NCT00308750 2021-05-13
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed
Clinical Trials
26 trialsNCT00533429 2021-05-13
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT00420381 2020-12-19
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00466440 2020-11-06
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
Eli Lilly and Company
Phase 2 Completed
NCT00415363 2020-11-05
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
Eli Lilly and Company
Phase 2 Completed
NCT00391118 2020-10-19
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
Eli Lilly and Company
Phase 2 Completed
NCT00542919 2020-10-19
A Study for Patients With Non-Hodgkin's Lymphomas
Eli Lilly and Company
Phase 2 Completed
NCT00744991 2020-10-19
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT00586508 2020-09-24
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
Eli Lilly and Company
Phase 2 Completed
NCT00414960 2020-09-21
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
Eli Lilly and Company
Phase 2 Completed
NCT00718419 2020-09-03
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Eli Lilly and Company
Phase 2 Completed
NCT00267020 2020-08-31
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00042666 2020-08-10
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
Eli Lilly and Company
Phase 2 Completed
NCT00192114 2020-08-06
Enzastaurin for Patients With Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00436280 2020-08-06
Chemotherapy for Participants With Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT00437268 2020-07-21
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00451178 2020-07-21
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Eli Lilly and Company
Phase 2 Completed
NCT00612586 2020-07-21
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00088205 2020-07-01
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT00530621 2020-07-01
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00309140 2020-06-26
An Open Label Study of Oral Enzastaurin in Participants With Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00451555 2019-11-01
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00509821 2019-04-05
Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
Eli Lilly and Company
Phase 2 Completed
NCT00475644 2018-11-05
A Study of Enzastaurin in Participants With Follicular Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT00105092 2007-05-01
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Eli Lilly and Company
Phase 2 Completed
NCT00190723 2007-01-26
A Study of LY317615 in Patients With Brain Tumors
Eli Lilly and Company
Phase 2 Completed